70 related articles for article (PubMed ID: 11751484)
41. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
[TBL] [Abstract][Full Text] [Related]
42. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hoekstra R; Dumez H; Eskens FA; van der Gaast A; Planting AS; de Heus G; Sizer KC; Ravera C; Vaidyanathan S; Bucana C; Fidler IJ; van Oosterom AT; Verweij J
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6908-15. PubMed ID: 16203782
[TBL] [Abstract][Full Text] [Related]
43. Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
Cura JE; Blanzaco DP; Brisson C; Cura MA; Cabrol R; Larrateguy L; Mendez C; Sechi JC; Silveira JS; Theiller E; de Roodt AR; Vidal JC
Clin Cancer Res; 2002 Apr; 8(4):1033-41. PubMed ID: 11948110
[TBL] [Abstract][Full Text] [Related]
44. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
45. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
46. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
[TBL] [Abstract][Full Text] [Related]
47. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Soepenberg O; de Jonge MJ; Sparreboom A; de Bruin P; Eskens FA; de Heus G; Wanders J; Cheverton P; Ducharme MP; Verweij J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):703-11. PubMed ID: 15701859
[TBL] [Abstract][Full Text] [Related]
48. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.
Horti J; Juhasz E; Monostori Z; Maeda K; Eckhardt S; Bodrogi I
Cancer Chemother Pharmacol; 2008 Jun; 62(1):173-80. PubMed ID: 18214483
[TBL] [Abstract][Full Text] [Related]
49. The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule.
Sola F; Capolongo L; Moneta D; Ubezio P; Grandi M
Cancer Chemother Pharmacol; 1999; 43(3):241-6. PubMed ID: 9923555
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of recombinant human endostatin in patients with advanced solid tumors.
Herbst RS; Hess KR; Tran HT; Tseng JE; Mullani NA; Charnsangavej C; Madden T; Davis DW; McConkey DJ; O'Reilly MS; Ellis LM; Pluda J; Hong WK; Abbruzzese JL
J Clin Oncol; 2002 Sep; 20(18):3792-803. PubMed ID: 12228199
[TBL] [Abstract][Full Text] [Related]
51. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.
Mita MM; Spear MA; Yee LK; Mita AC; Heath EI; Papadopoulos KP; Federico KC; Reich SD; Romero O; Malburg L; Pilat M; Lloyd GK; Neuteboom ST; Cropp G; Ashton E; LoRusso PM
Clin Cancer Res; 2010 Dec; 16(23):5892-9. PubMed ID: 21138873
[TBL] [Abstract][Full Text] [Related]
52. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
Eder JP; Supko JG; Clark JW; Puchalski TA; Garcia-Carbonero R; Ryan DP; Shulman LN; Proper J; Kirvan M; Rattner B; Connors S; Keogan MT; Janicek MJ; Fogler WE; Schnipper L; Kinchla N; Sidor C; Phillips E; Folkman J; Kufe DW
J Clin Oncol; 2002 Sep; 20(18):3772-84. PubMed ID: 12228197
[TBL] [Abstract][Full Text] [Related]
53. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours.
de Jonge MJ; Verweij J; van der Gaast A; Valota O; Mora O; Planting AS; Mantel MA; Bosch SV; Lechuga MJ; Fiorentini F; Hess D; Sessa C
Eur J Cancer; 2002 Dec; 38(18):2407-15. PubMed ID: 12460785
[TBL] [Abstract][Full Text] [Related]
54. Phase I study of the novel distamycin derivative tallimustine (FCE 24517).
Sessa C; Pagani O; Zurlo MG; de Jong J; Hofmann C; Lassus M; Marrari P; Strolin Benedetti M; Cavalli F
Ann Oncol; 1994 Dec; 5(10):901-7. PubMed ID: 7696161
[TBL] [Abstract][Full Text] [Related]
55. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone.
Petty WJ; Miller AA; McCoy TP; Gallagher PE; Tallant EA; Torti FM
Clin Cancer Res; 2009 Dec; 15(23):7398-404. PubMed ID: 19920106
[TBL] [Abstract][Full Text] [Related]
56. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
57. Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use.
Chiodelli P; Bugatti A; Urbinati C; Rusnati M
Molecules; 2015 Apr; 20(4):6342-88. PubMed ID: 25867824
[TBL] [Abstract][Full Text] [Related]
58. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.
Groen HJ; de Vries EG; Wynendaele W; van der Graaf WT; Fokkema E; Lechuga MJ; Poggesi I; Dirix LY; van Oosterom AT
Clin Cancer Res; 2001 Dec; 7(12):3928-33. PubMed ID: 11751484
[TBL] [Abstract][Full Text] [Related]
59. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
60. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
